Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

DECEMBER 23, 2021

billion by 2025. The market sizing section provides forecasts on the estimated sales of the three most lucrative cannabinoid pharmaceuticals – from 2021-2025 – including Epidiolex, Sativex and Dronabinol. Global surveys of cannabis users indicate that around 40% of users have some medical component to their usage.

Pharmaceutical 96

Pharmaceutical Clinical Trials Research and Development Cannabinoids 96

Cannabis Law Report

FEBRUARY 9, 2022

There’s also concern about a rare condition known as wood lover’s paralysis , a condition that produces muscle weakness a few hours after hallucinogenic mushrooms are consumed. Scientists don’t know why this condition occurs, but it isn’t believed to happen with Psilocybe cubensis. Other species might be introduced later.

Clinical Trials 52

Clinical Trials Microdosing Safety Conditions 52

Cannabis Law Report

NOVEMBER 16, 2021

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), tumor necrosis factor receptor I (TNFRI) and IL-6.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 15, 2021

Although a limited number of CGTs are currently on the market, FDA officials predicted in 2019 that the agency will receive more than 200 investigational new drug applications per year for cell and gene therapies and that by 2025, it expects to have accelerated to 10 to 20 cell and gene therapy approvals per year 1.

Research and Development 52

Research and Development Therapy Clinical Trials Supply Chain 52

Cannabis Law Report

JANUARY 5, 2022

3 MyMD believes that there are no FDA-approved drugs for treating aging disorders and extending healthy lifespan in humans, a market expected to be at least $600 billion by 2025 according to a major investment bank. In the United States, the estimated cost of hospitalizations in individuals with sarcopenia is estimated at $40.4

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

The Joint Blog

JULY 25, 2020

organic food market by 2025 is at $70.4 The agency maintains that they need more time to probe further into the science of cannabidiol, which will require thorough research and clinical trials before they can conclude certain products as GRAS. “To It has been predicted that the U.S CBD Products and the FDA The U.S.

CBD 33

CBD Clinical Trials Safety Media 33